Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival

Peptide‐based vaccines have led to the induction of antigen‐specific CD8+ T‐cell responses in patients with NY‐ESO‐1 positive cancers. However, vaccine‐induced T‐cell responses did not generally correlate with improved survival. Therefore, we tested whether a synthetic CpG 7909 ODN (deoxycytidyl‐deoxyguanosin oligodeoxy‐nucleotides) mixed with NY‐ESO‐1 peptide p157‐165 and incomplete Freund's adjuvants (Montanide® ISA‐51) led to enhanced NY‐ESO‐1 antigen‐specific CD8+ immune responses in patients with NY‐ESO‐1 or LAGE‐1 expressing tumors. Of 14 HLA‐A2+ patients enrolled in the study, 5 patients withdrew prematurely because of progressive disease and 9 patients completed 1 cycle of immunization. Nine of 14 patients developed measurable and sustained antigen‐specific CD8+ T‐cell responses: Four had detectable CD8+ T‐cells against NY‐ESO‐1 after only 2 vaccinations, whereas 5 patients showed a late‐onset but durable induction of NY‐ESO‐1 p157‐165 specific T‐cell response during continued vaccination after 4 months. In 6 patients, vaccine‐induced antigen‐specific T‐cells became detectable ex vivo and reached frequencies of up to 0.16 % of all circulating CD8+ T‐cells. Postvaccine T‐cell clones were shown to recognize and lyse NY‐ESO‐1 expressing tumor cell lines in vitro. In 6 of 9 patients developing NY‐ESO‐1‐specific immune responses, a favorable clinical outcome with overall survival times of 43+, 42+, 42+, 39+, 36+ and 27+ months, respectively, was observed.

[1]  J. Wolchok,et al.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit , 2008, Proceedings of the National Academy of Sciences.

[2]  A. Iasonos,et al.  Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission , 2008, Clinical Cancer Research.

[3]  J. Karbach,et al.  Tumor‐reactive CD8+ T‐cell clones in patients after NY‐ESO‐1 peptide vaccination , 2007, International journal of cancer.

[4]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[5]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[6]  D. Jäger,et al.  Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients , 2006, Proceedings of the National Academy of Sciences.

[7]  L. Old,et al.  Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients , 2006, Journal of immunotherapy.

[8]  L. Old,et al.  In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. , 2006, The Journal of clinical investigation.

[9]  A. La Cava,et al.  CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. , 2006, Trends in immunology.

[10]  K. Odunsi,et al.  Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination1 , 2006, The Journal of Immunology.

[11]  D. Purcell,et al.  Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. , 2006, Vaccine.

[12]  D. Speiser,et al.  Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. , 2006, Cancer research.

[13]  D. Speiser,et al.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.

[14]  J. Marshall,et al.  Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Akira,et al.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.

[16]  P. Coulie,et al.  Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1 , 2003, The Journal of Immunology.

[17]  K. Itoh,et al.  Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination , 2003, The Prostate.

[18]  Danila Valmori,et al.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. , 2002, The Journal of clinical investigation.

[19]  S. Ascarateil,et al.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines , 2002, Expert review of vaccines.

[20]  S. Akira,et al.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  V. Engelhard,et al.  Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients , 2001, International journal of cancer.

[22]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[23]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  V. Cerundolo,et al.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Speiser,et al.  Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.

[26]  V. Cerundolo,et al.  Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1 , 2000, The Journal of Immunology.

[27]  P. Kantoff,et al.  A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[30]  S. Groshen,et al.  Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  D. Jäger,et al.  Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. , 1999, International journal of cancer.

[32]  G. Hartmann,et al.  CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Klenerman,et al.  CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines , 1999, Journal of Virology.

[34]  L. Vinner,et al.  Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. , 1999, Vaccine.

[35]  K. Heeg,et al.  CpG‐oligodeoxynucleotides co‐stimulate primary T cells in the absence of antigen‐presenting cells , 1999, European journal of immunology.

[36]  L. Hültner,et al.  Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. , 1999, Journal of immunology.

[37]  G. Weiner,et al.  Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Pircher,et al.  On the role of antigen in maintaining cytotoxic T-cell memory. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Krieg,et al.  Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. , 1996, Journal of immunology.

[40]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[41]  J. Sprent,et al.  Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro , 1996, The Journal of experimental medicine.

[42]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[43]  D. Speiser,et al.  Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. , 2004, Cancer immunity.

[44]  M. Jefford,et al.  The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. , 2004, Cancer immunity.

[45]  S. Aamdal,et al.  Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.

[46]  F. Marincola,et al.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.

[47]  A. Lohse,et al.  Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. , 1996, Journal of immunological methods.